ClinicalTrials.gg
CompletedNCT02355899Updated Sep 19, 2017

Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail.

A Phase 2 interventional study of PD P 506 A in Onychomycosis, sponsored by photonamic GmbH & Co. KG. Completed at 2 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-09-19.

Sponsored by photonamic GmbH & Co. KG (formerly part of medac GmbH) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study evaluates the potential usefulness of photodynamic therapy with PD P 506 A in patients with distal subungual onychomycosis of the great toenail. Patients will receive four PDT treatments with PD P 506 A in weekly intervals.

02

Conditions studied

  • Onychomycosis

Browse trials for

03

In context

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

This study's enrollment of 25 is below the median of 60 across 143 interventional studies indexed under Onychomycosis.

Browse Onychomycosis studies →

Lead sponsor

photonamic GmbH & Co. KG is the lead sponsor of 7 studies on the registry; none are open to participants now.

First submitted before photonamic GmbH & Co. KG left medac GmbH.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male 18 - 75 years of age
  • Females up to an age of 75 years provided that they are , i.e. with spontaneous amenorrhea for at least 12 months or not of because of tubal ligation or hysterectomy
  • DSO of at least one of the great toe(s) affecting 20% to 60% of the target nail without spikes, confirmed before Visit 1 by at least one of the three methods: the methods of KOH test, periodic acid-Schiff (PAS) stain and mycology culture
  • The toenail infection can be due to a dermatophyte, yeast or mixed infections (dermatophyte and non-dermatophyte)
  • Toenails have to be cut regularly (indicator for existing growth)
  • Signed written

Exclusion criteria

Exclusion Criteria:

  • Patients with the target toenail involving the matrix (lunula) or having less than 2 mm clear (unaffected) nail plate length beyond the proximal fold
  • Presence of dermatophytoma (defined as demarcated and localised thick masses (≥ 3 mm) of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail
  • Other conditions than DSO known to cause abnormal nail appearance
  • Topical antifungal treatment of the nails within 1 month before PDT
  • Systemic use of antifungal treatment within 3 months before PDT
  • Patients who are unwilling to provide nail clippings
  • Patients who have been previously reported to be allergic against 5-aminolevulinic acid or other ingredients of PD P 506 A
  • Diagnosis of porphyria
  • Diagnosis of polyneuropathy
  • Dementia or psychic condition that might interfere with the ability to understand the study and thus give written
  • Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    PD P 506 A-PDT

    One PD P 506 A-patch will be administered to each great toenail for 4 hours. After removal of the study medication the study nail(s) s will be illuminated with red light of defined wavelength (PDT).

    Drug: PD P 506 A

Interventions

  • PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².

    Also known as: Alacare®

06

What researchers measure

Primary outcomes

  1. Percentage of nails with Clinically Complete Cure

    The Complete Clinical Clearance of each treated nail will be determined 3, 6 and 12 months after last study treatment. Based on a visual inspection, the nail(s) will either be defined as "completely cleared" or "partially" or "not cleared". To be defined as "completely cleared", a nail must show 100% absence of the 4 following clinical signs of onychomycosis (according to Scher et al., J Am Acad Dermatol. 2007 Jun;56(6):939-44): * Residual changes of the nail plate compatible with dermatophyte infection * White/yellow or orange brown/patches or streaks in or beneath the nail * Lateral onycholysis with debris in an otherwise clear nail plate * Hyperkeratoses on the lateral nail plate/nailfold edge. If the nail shows an improvement but still one of the above signs, it will be rated as "partially cleared". If the nail shows no improvement in comparison to the Screening Visit, it will be rated as "not cleared".

    Time frame: 12 months after last study treatment

Secondary outcomes

  1. Percentage of nails with negative laboratory test results for onychomycosis (KOH test, periodic acid-Schiff (PAS) stain and mycology culture).

    Time frame: 12 months after last study treatment

  2. Percentage of nails with Clinically Complete Cure

    The Complete Clinical Clearance of each treated nail will be determined 3, 6 and 12 months after last study treatment. Based on a visual inspection, the nail(s) will either be defined as "completely cleared" or "partially" or "not cleared". To be defined as "completely cleared", a nail must show 100% absence of the 4 following clinical signs of onychomycosis (according to Scher et al., J Am Acad Dermatol. 2007 Jun;56(6):939-44): * Residual changes of the nail plate compatible with dermatophyte infection * White/yellow or orange brown/patches or streaks in or beneath the nail * Lateral onycholysis with debris in an otherwise clear nail plate * Hyperkeratoses on the lateral nail plate/nailfold edge. If the nail shows an improvement but still one of the above signs, it will be rated as "partially cleared". If the nail shows no improvement in comparison to the Screening Visit, it will be rated as "not cleared".

    Time frame: 3 and 6 months after last study treatment

  3. Frequency of adverse events

    Time frame: During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment

  4. Severity (grade1-5) of adverse events

    The severity of AEs is defined as: * Grade 1 = mild * Grade 2 = moderate * Grade 3 = severe * Grade 4 = life-threatening * Grade 5 = fatal

    Time frame: During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment

  5. Frequency of local reactions.

    Photodynamic therapy is intended to produce a phototoxic reaction, which is part of the desired effect. After PDT, treated toes may show local reactions such as redness and swelling.

    Time frame: During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment

  6. Severity (grade1-3) of local reactions.

    The severity of local reactions is defined as: * Grade 1 = mild * Grade 2 = moderate * Grade 3 = severe

    Time frame: During the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment

  7. One photo of each treated toenail at the beginning of each visit

    Documentation of the course of the study for each treated toenail.

    Time frame: At screening visit (up to 4 weeks before first treatment), during the treatment phase on day 0, 7, 14 and 21, and 3, 6 and 12 months after last study treatment.

07

Study locations

2 sites
  • Klinik für Dermatologie, Klinikum Lippe
    Detmold, 32756, Germany
  • Klinik für Dermatologie und Allergologie KLINIKUM VEST GMBH Knappschaftskrankenhaus Recklinghausen
    Recklinghausen, 45657, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2015
First posted
Feb 4, 2015
Start
Jan 2015
Primary completionActual
Aug 23, 2017
CompletionActual
Aug 23, 2017
Last update
Sep 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02355899
Responsible party
Sponsor
First posted
Feb 4, 2015
Start date
Jan 2015
Primary completion
Aug 23, 2017
Completion
Aug 23, 2017
Last update
Sep 19, 2017

Study contacts

Rolf-Markus Szeimies, Prof. Dr.
principal investigator · KLINIKUM VEST GMBH Knappschaftskrankenhaus Recklinghausen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aminolevulinic Acid

Start the discussion